Navigation Links
Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
Date:10/9/2009

FREISING-WEIHENSTEPHAN, Germany, October 9 /PRNewswire/ -- Pieris AG, the biopharmaceutical company developing Anticalins as a novel class of targeted human protein therapeutics, today reported continued progress in development of its lead therapeutic program for the clinic.

Under its manufacturing agreement with Wacker Biotech GmbH, a full-service contract manufacturer of biopharmaceuticals, Pieris has successfully completed the first cGMP run of its Anticalin candidate PRS-050, a potent VEGF antagonist with broad therapeutic applicability.

Having established production process parameters for PRS-050 earlier in 2009, Pieris has now met all regulatory CMC requirements to file an IND application by the end of January 2010. With toxicology studies running concurrently, PRS-050 is scheduled to commence first in man studies in the first half of 2010. Progress in the PRS-050 program demonstrates that Anticalin discovery programs can be successfully advanced from lead candidate to GMP production in around twelve months.

Commenting on these developments at Pieris, Claus Schalper, interim-CEO, said: "Sustained progress in development of PRS-050 underscores our commitment to advancing our lead Anticalin program into the clinic as quickly and efficiently as possible. This is in line with Pieris' strategy to bring Anticalins into the clinics while partnering selected project at an earlier development stage."

About Pieris AG

Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins, a novel class of targeted human proteins designed to diagnose and treat serious human disorders. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the company applies a balanced risk business model to the development of Anticalin product candidates.

About Anticalin Technology

Anticalins a
'/>"/>

SOURCE Pieris AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pieris AG Enters into Anticalin Collaboration With Allergan, Inc.
2. Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round
3. Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics
4. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
5. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
6. Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
7. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009
8. Economic Strength of Hawaii Seed Crop Industry Confirmed by Recent Reports
9. Anpath Group, Inc. Reports Progress in Japanese Market
10. Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
11. YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Greenville, SC (PRWEB) August 22, 2014 ... that indisputable acknowledgement is a national disgrace. Furthermore, ... part in establishing the current, deplorable state of ... outlined "5 great mistakes," to merely serve as ... convey the extent of colossal failure(s) that have ...
(Date:8/21/2014)... team including DESY scientists has observed tiny quantum vortices ... in the journal Science that the exotic ... nanodroplets. It is the first time that the quantum ... of what is known as superfluid helium, have been ... expectations," says Andrey Vilesov of the University of Southern ...
(Date:8/21/2014)... , Aug. 21, 2014 Telomere Biosciences, ... their Nutraceutical "TELO-20 for Dogs" with Telomerase ... supplement in the world for dogs. Telomeres are ... chromosome in the body. A wealth of ground-breaking ... in Telomere Science and Aging, including Nobel laureates, ...
(Date:8/21/2014)... 2014 OTC Markets Group Inc. ... biotechnology company, on its approval to list on ... OTCQX®, the best marketplace for established U.S. and ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... of its growth strategy and achievement of this ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Scientists observe quantum vortices in cold helium droplets 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... BioSciences, Inc. (OTC Bulletin Board: GNLK ... that it ranked number 33 on Technology Fast 500 ... growing technology, media, telecommunications, life sciences and clean technology ... the period 2006-2010. GeneLink,s chief executive ...
... Inc ., a late-stage epigenetics oncology company, announced today that members ... BIO Investor Forum , San Francisco, CA, October ... Target , Panel Discussion: HDACi and Their Progress in the Clinic, ... Healthcare Conference , New York, NY, November 16, 1:30 PM ET ...
... 24, 2011 Modern Plastics, one of the largest ... plastics, has become ISO 13485-2003 certified for the distribution ... Resin. "This is an extraordinary achievement ... service and quality," said Bing J. Carbone, President at ...
Cached Biology Technology:GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™ 2GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™ 3Syndax Pharmaceuticals to Present at Upcoming Fall Conferences 2
(Date:8/21/2014)... of researchers at Louisiana Tech University has ... consumer-grade 3D printers and materials to fabricate ... and chemotherapeutic compounds for targeted drug delivery. ... and research faculty from Louisiana Tech,s biomedical ... create filament extruders that can make medical-quality ...
(Date:8/21/2014)... resulting in severe abdominal pain, vomiting and systemic inflammation. ... diagnosed with the disease resulting in 1000 deaths. There ... intravenous fluid and nutritional support. , Dr Jason ... the research, said "The major causes of pancreatitis include ... intake combined with a high fat diet. In fact, ...
(Date:8/20/2014)... Researchers at Huntsman Cancer Institute (HCI) at the University ... the gene that encodes BCR-ABL, the unregulated enzyme driving ... the American Cancer Society, nearly 6,000 new cases of ... in use, called tyrosine kinase inhibitors (TKIs), target BCR-ABL ... not cure CML but control it in a way ...
Breaking Biology News(10 mins):Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Insulin offers new hope for the treatment of acute pancreatitis 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... the Smithsonian Institution and the Hawaii Institute of Marine ... created the first frozen bank for Hawaiian corals in ... preserve their diversity in Hawaii. Mary Hagedorn, an adjunct ... the Smithsonian Conservation Biology Institute, leads the laboratory at ...
... underlay many cancers. Rui Martinho at the Instituto Gulbenkian ... in Ghent (Belgium) and Bergen (Norway) will use the ... identified in the test-tube, impact on the way cells ... the Association for International Cancer Research (AICR), will provide ...
... of an old antibiotic may help diabetics avoid a stroke ... researchers report. Minocycline, a drug already under study at ... blood vessels in the brain that increases their stroke risk ... Dr. Adviye Ergul, physiologist in the MCG Schools of Medicine ...
Cached Biology News:Smithsonian scientists help create first frozen repository for Hawaiian coral 2Understanding cancer using the fruit fly 2Antibiotic may reduce stroke risk and injury in diabetics 2
... Desselberger (1995) • This book is ... classical and molecular techniques currently used ... and analysis of virus-specific antibodies and ... presented covering immunoassays, blotting and hybridization ...
Bovine Serum...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
2.0 GHz Compaq Computer with 512 MB RAM, 32 MB AGP Graphics Card, 40 GB Hard Drive, 1 Serial Port & Open PCI Slot, Windows 2000 OS, MS Office, CD Read/Writer and 18 Flat Panel Monitor...
Biology Products: